© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Decades ago, scientists at BASF set out to push the boundaries in nonionic surfactants, chasing ways to stabilize formulations and bring fresh solutions to classic chemistry challenges. The poloxamer line grew from those experiments, with P407 and F127 soon taking center stage. They didn’t become favorites just because of luck. Chemists noticed right away how these block copolymers balanced hydrophobic and hydrophilic segments, opening doors for pharmaceutical formulations. Over the years, journals filled with reports about their gel-forming abilities, helping researchers leap into fields like controlled drug delivery, wound care, and even cosmetics. Poloxamer P407 and F127 didn’t just stick around, they shifted standards across several industries.
In practical terms, Poloxamer P407 and F127 stand out because of their structure: polyethylene oxide and polypropylene oxide blocks repeating in patterns that bring predictability to viscosity and solubility. Pharmaceutical manufacturers prize these copolymers, not for theory, but for results—turning liquids into reversible gels, forming clear solutions, and holding formulations steady at body temperature. Feeding off their strong performance in real-world trials, suppliers around the globe push these poloxamers under names like Pluronic F127 and Synperonic PE/F127, making them staples in research kits and product ingredient lists.
Poloxamer P407 and F127 gain trust not from fancy chemical diagrams but from their reliability. The typical white, waxy powder dissolves with patience in cold water, then transforms into a firm gel as things heat up. That thermal gelling property—liquid at low temps, gel at higher—brings practical value to anyone working on temperature-sensitive products. Their amphiphilic makeup—meaning one end binds water, the other shuns it—gives them the muscle to solubilize tricky actives, hold emulsions together, and keep particulates in check. The average molecular weight for P407 usually sits around 12,600 Da, while F127 is somewhat lower. Their stable, non-irritating nature means these compounds quietly do their job without causing problems, day in, day out.
Farmers, pharmacists, and researchers all read the fine print before committing to ingredients. For P407 and F127, technical data sheets from suppliers line up batch consistency, molecular weight distribution, and HLB (hydrophilic-lipophilic balance) without much room for surprises. Labels usually mention storage conditions—cool, dry, tightly sealed—because moisture turns the neat powder into clumps. Standards set by the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) put a lid on impurities, making sure what’s on the label tracks with what ends up in production. Companies keep close to pharmacopeial requirements and track lot records, because safety audits or regulatory inspections are real and unforgiving in critical applications.
Producing P407 and F127 takes more than just mixing chemicals. Manufacturers start with propylene oxide and ethylene oxide—key raw materials in the petrochemical world. Through controlled polymerization, they add these oxide rings in precise order, using catalysts like potassium hydroxide. The process grows the polymer chain with surgical precision, alternating hydrophobic and hydrophilic sections until the final material matches the blueprint. Quality control teams sample, test, and reject batches that don’t land inside tight windows for viscosity, cloud point, or residual monomer content. After drying and milling, the pure product makes its way into drums or bags, waiting for its next life in a new formulation.
Poloxamers, by design, keep their chemistry simple. They resist hydrolysis and oxidation, which means shelf stability doesn’t keep anyone up at night. That said, researchers continue tweaking these copolymers to fit specialized needs. Attaching carboxyl or amine groups along the polymer backbone tunes drug binding, while conjugating ligands or dyes creates targeted delivery systems for diagnostics or imaging. Some labs invest in crosslinking strategies, looking for gels that hold up longer in the body or offer slower release for embedded drugs. Every modification method still needs a careful balance—change the polymer too much and it loses its winning features, but smart chemistry adds another arrow in the quiver for innovators.
No shortage of aliases pop up across the supply chain. “Poloxamer 407,” “Pluronic F127,” “Synperonic PE/F127,” and “Lutrol F127” all point back to the same backbone. Generics and branded versions crisscross catalogs from Sigma-Aldrich to Croda to local suppliers in Asia and Europe. For regulatory filings, correct International Nomenclature Cosmetic Ingredient (INCI) names must show up on product packaging, or risk slowing down market approval. People working in regulated industries keep spreadsheets on matching synonyms to lot numbers, avoiding mix-ups during audits or recalls.
Unlike many synthetic surfactants, Poloxamer P407 and F127 draw very little concern from safety officers. Labs regularly run skin irritation, cytotoxicity, and sensitization studies; both compounds consistently turn up negative for harmful effects under normal use. Their nonionic structure means interactions with tissue or active ingredients don’t often trigger surprises. Despite this track record, facilities handling bulk quantities install dust control and appropriate ventilation, because inhaling powders poses risks unrelated to the polymer itself. Cleaning protocols handle spills without aggressive solvents, and safety data sheets from every major supplier reinforce the norm of responsible handling. Anyone preparing drug products with these polymers can sleep a little easier knowing safety records don’t get marked up very often.
Poloxamer P407 and F127 take leading roles in fields that reward versatility. Hospitals fill syringes and ointment tubes with hydrogels based on these polymers, providing local delivery where liquid formulations used to run off the target. Pharmaceutical companies wrap hazardous chemotherapy drugs in micelles made of F127, protecting both caregivers and patients from unwanted exposure. Cosmetics lines harness P407’s power to suspend exfoliants in scrubs and upend the “layering” game in high-end skincare serums. In labs, molecular biologists grow cells atop poloxamer gels, supporting delicate structures that hate stiff traditional plastics. Even industrial companies steer away from older surfactants or toxic solvents by relying on poloxamers to disperse flavors in foods, lubricants in manufacturing, or actives in cleaning products.
Innovation in drug delivery leans heavily on the properties of P407 and F127. Scientists adjust concentration, tweak solution pH, and mix in other excipients, chasing better performance for injectable depot systems or fast-dissolving oral strips. The easy customization brings these polymers into the mix for nose-to-brain delivery strategies and transdermal gels that outperform patches. Startups and research consortia line up to publish new ways to combine poloxamers with biodegradable polymers like chitosan or alginate, unlocking hybrid systems loaded with smart-release triggers responding to disease markers or environmental signals. The drive for patient-centered, convenient treatments keeps research groups pushing the flexibility and compatibility of these polymers in both new devices and clever dosage forms.
Poloxamer P407 and F127 don’t just get waved through regulatory review. Toxicologists and clinical researchers pore over every study: oral, dermal, intravenous, and inhalation exposure across animal models and human volunteers. Consistent findings show rapid excretion, negligible absorption, and lack of organ accumulation—attributes that offer a certain peace of mind. High-dose animal studies push these polymers far above human exposure levels, but still seldom turn up adverse outcomes beyond mild GI upset at the margins. Post-marketing surveillance, especially for eye care and wound-healing applications, keeps real-world vigilance high, and so far, both poloxamers keep their reputation clean.
The story of Poloxamer P407 and F127 runs far from its last chapter. Biotechnology fields chase smart, responsive gels that adjust to temperature, pH, or even light. Drug makers explore nanoparticle suspensions that hide sensitive molecules from immune attack, aiming for better cancer treatments with fewer side effects. Tissue engineers use poloxamer scaffolds for growing organoids, seeing hope for transplant-ready tissue grown on a backbone that dissolves safely. Startups enter the scene, drawn by patents for new wound care foams or consumer health products that span solid to liquid in a blink. Pressure from green chemistry pushes manufacturers to cut process emissions, build renewable supply chains, and ensure these polymers never trigger freshwater or aquatic toxicity. The next decade looks set to test how fast suppliers and inventors adapt to growing demand for sustainability, all while keeping the reliability and low cost that made poloxamers a mainstay in medicine and beyond.
Poloxamer P407, also called F127, turns up in a lot of things without most people ever noticing. Flip over the ingredient label on some topical creams or gels prescribed from the pharmacy, and there it is. Hospitals keep it on hand for specialized drug delivery because of one clever trick: this polymer starts off as a liquid at cooler temperatures and thickens up into a firm gel when warmed. That single feature makes it valuable for doctors who need to apply medicine at body temperature so it stays put. It also makes formulating eye drops less miserable for people who hate those watery drops that run down the face.
Take a cancer patient who needs local chemotherapy without blasting their whole body with toxic drugs. Researchers use Poloxamer P407 to wrap up medications in a gel that forms right at the tumor site, holding the medicine exactly where it’s needed. Fewer side effects, better results. I’ve watched friends and family struggle through the side-effects of systemic chemotherapy, so solutions like this aren’t just interesting—they’re personal. I’ve seen people dealing with skin wounds after radiation therapy, or fighting off pain from chronic ulcers, and gels with this polymer really do make an everyday difference. You can apply medicine, close up the wound, and let the body focus on healing.
Pharmacies and biotech companies know F127’s value, but it also shows up in things most wouldn’t expect. You’ll find it in some mouthwashes, letting active ingredients stick around in your mouth instead of disappearing straight down your throat. Even in contact lens solutions, it helps keep lenses wet and comfortable. Diabetics may be interested to know that Poloxamer P407 can be used in new insulin formulations designed to release at just the right speed. As a parent of a child with Type 1 diabetes, I know the challenges of balancing blood sugar—innovation in this area brings hope by promising fewer injections or steadier glucose levels.
Most folks don’t worry about how a gel forms or why a cream doesn’t slide off the skin. The science behind it really does matter, though. This stuff is considered pretty safe, and it doesn’t trigger many allergies. That’s not always the case with new pharmaceutical ingredients. Debate still breaks out around long-term environmental build-up, since synthetic polymers have a way of sticking around. But with decades of use in clinics and everyday products, most safety studies put concerns to rest for personal use.
Poloxamer P407 shines in areas where doctors, patients, and pharmacists want better results without extra pain, mess, or irritation. Smart researchers keep coming up with new uses—think of dissolvable implants for pain relief after surgery, or gels delivering antibiotics to hard-to-treat infections. Patient comfort improves, and recovery often speeds up. It reminds me every day that good science isn’t hiding away in some forbidden lab; it’s in your medicine cabinet, quietly changing lives.
It’s easy to glance past a name like Poloxamer P407. Understanding what sits behind that name does more than satisfy curiosity. This polymer highlights how a bit of chemical ingenuity improves lives, offering real-world benefits in ways that most people never notice. As technology grows, we’re bound to see even more new applications, and that’s worth keeping on our radar—especially for folks dealing with tough health challenges.
Poloxamer P407, also known as F127, pops up in a lot of products from daily use to specialized hospital settings. As a nonionic surfactant and triblock copolymer, it blends in seamlessly with personal care items, drug delivery systems, and even contact lens solutions. Personal experiences with gels and ointments can often be traced back to this ingredient, which gives products their smooth texture. Its ability to form gels at body temperature turns it into a trustworthy tool in medicine and pharmaceutical science.
The U.S. Food and Drug Administration lists Poloxamer 407 on the Inactive Ingredients Database, which means it has been reviewed and cleared for use in several medications and topical formulations. Regulatory bodies in Europe and Japan also acknowledge its role in food and pharmaceuticals.
Dose matters more than anything else in safety. In everyday cosmetics like shampoo or toothpaste, the concentration of Poloxamer 407 stays low. Most people rub these products on and rinse them off without a problem. The story changes a bit with injectable drugs. High doses can tip the scale — as shown in a few animal studies where extremely high concentrations led to cholesterol buildup and other side effects.
Poloxamer 407 has walked through years of research. Scientists point out that after topical or oral exposure, the compound doesn’t easily absorb into the body. It gets flushed out, mostly unchanged. One long-term study lodged in my mind: volunteers used Poloxamer-based mouthwash for months, and no increased risk for oral lesions or irritation showed up. Allergic reactions exist but fall into the rare category.
Animal studies have chased after potential dangers. Mice exposed to huge doses showed increased blood lipid levels, so researchers flagged this for special attention. Humans rarely reach those levels; therapeutic and food-grade use sits far below the danger zone. That said, anyone with a rare metabolic condition or unusual cholesterol sensitivity should talk to a physician about any concerns.
Besides its spot in consumer goods, doctors have found ways to use Poloxamer 407 in wound healing and drug delivery. Hospitals use its unique property of forming hydrogels that melt at cold temperatures and firm up at body heat. This trick helps deliver medications in a slow, precise way. Oversight by hospital pharmacists and regulatory committees limits risks of accidental overdose.
For researchers exploring new applications, the principles of safe dosing and thorough patient screening carry more weight than the ingredient itself. Doctors and scientists face the challenge of weighing benefits and risks with new therapies.
Consumers can check product labels and choose trusted manufacturers, especially for items meant to linger on the skin or stay in contact with the eyes or mouth. Those who react to new skincare products should stop and consult a doctor. The rest of us probably have already crossed paths with Poloxamer 407 and gone about our day unharmed. Staying informed through reliable health websites, talking to pharmacists, and keeping an eye on regulatory updates remain wise choices for anyone concerned about ingredients in their daily lives.
Poloxamer P407, also known as F127, stands out among pharmaceutical excipients for its unusual mix of water solubility and thermoresponsive behavior. This synthetic polymer, built from blocks of ethylene oxide and propylene oxide, has a knack for forming clear gels when the temperature rises. At cold temperatures, solutions flow easily like water; raise the temperature, and the liquid turns into a soft solid gel. In practical terms, this property smooths the way for a lot of modern drug delivery solutions, especially in wound care and topical treatments where a product has to be easy to apply but stay put on the skin.
Most researchers recognize the way P407 dissolves in both water and alcohols. In my own lab work, I’ve found that this solubility helps with making homogeneous mixtures, cutting down on the unpleasant lumps that sometimes crop up with other polymers. That means patients get the correct dosage every time, a key detail in clinical care. P407 also works well alongside many active drugs, preservatives, and even dyes, without causing irritation or toxic responses.
P407 solutions are not just water-thickening agents — their thermoresponsive behavior means you can create gels right at body temperature. For example, a solution can be kept cool and in liquid form for easy injection or spreading, then it gels once it contacts warm skin or muscle. Hospitals and clinics value this for wound coverings, postoperative care, and sustained drug release, as the material doesn’t slide off after it’s been applied. You see this approach in nasal sprays, ophthalmic treatments, and even injectable long-acting medications. Gelation temperature can be adjusted based on formulation, but the sweet spot sits near body temperature, making applications direct and patient-friendly.
Anyone who’s handled patient samples knows the importance of products that don’t cause allergic reactions or harm tissue. Tests from respected sources like the FDA and EMA show that P407 has a strong safety track record, even with repeated applications. The molecule doesn’t hang around in tissues; the kidneys can process and remove it. Researchers appreciate that they don’t have to worry about it breaking down into toxic byproducts, either. This makes it a regular choice for eye drops, local anesthetics, and pediatric medicines.
Controlled release sits at the core of many modern medical treatments. P407’s gel-making ability helps deliver medicines slowly over time. It acts as a gatekeeper for the active drug, letting it leak out at a steady pace. I’ve seen projects use this feature to cut dosing frequency for painkillers, antibiotics, and even anti-cancer treatments. Patients benefit: there’s less pain from frequent dosing, fewer reminders needed, and a lower risk of overdosing from a sudden drug burst.
Even well-established materials have limits. With Poloxamer P407, the main snag shows up as gel erosion — the material slowly dissolves when soaked in body fluids. This can mean that drug release doesn’t last as long as hoped in some applications. Scientists and pharmacists tackle this by blending P407 with other polymers such as carbomers or hyaluronic acid, or by tweaking the concentrations and pH of their solutions. Through trial, error, and careful observation, they keep finding ways to match the polymer to each specific patient need. This steady drive toward better solutions keeps P407 popular across clinics, compounding pharmacies, and research labs.
Anyone working in research labs or making products like pharmaceutical gels has probably heard of Poloxamer P407, also called F127. What makes this ingredient stand out? Flexibility. In the lab, F127 does more than just act as a thickener—it's a staple for prepping hydrogels, drug delivery systems, and even cleaning solutions for sensitive surfaces. Its reputation as a reliable crowd-pleaser isn't an accident. But before it can offer any of these benefits, there’s a simple step to get right: dissolving it in water.
Poloxamer F127 isn’t your average powder. While it looks harmless enough, this stuff will form clumps and sticky masses if you toss it straight into room-temperature water. Anyone who’s ever watched a solution go from clear to gummy knows the frustration. Skipping the right steps leads to wasted material and delays. In tight lab budgets or production deadlines, every wasted gram matters.
Chill Your WaterF127 dissolves best in cold water. Icy, not just “cool.” The reason comes down to the way its block copolymer chains behave—cold temperatures keep them extended and easy to hydrate, instead of curling up and sticking together. In my own experience, the difference between using fridge-cold water and tap temperature is night and day. Any fridge will work, or just drop some ice in a beaker and let it melt.
Add Powder GraduallyAvoid pouring all the powder in one heap. Sprinkle it in slowly, gently stirring the entire time. It sounds tedious, but this prevents the dreaded formation of gel blobs that never seem to dissolve. Once, when hurrying, dumping all the powder ended up taking twice as long to fix. Patience pays off here.
Keep Stirring… and WaitingThis part always tests patience. Even in cold water, F127 will take several hours to fully dissolve. Leave the container on a magnetic stirrer overnight if possible, or use a hand stirrer and check back after a few hours. Sometimes, clear mixing doesn’t mean it’s ready—fine undissolved specks may linger if you skip this wait.
The temptation to cut corners creeps in for scientists and manufacturers alike. Impatience in prepping F127 means poor texture in formulations, unstable drug release, or even failed experiments. I’ve seen plenty of wasted batches from shortcuts on this step, leading to lost time and resources. Too many projects fizzle because a product didn’t dissolve cleanly, throwing off all the following work. It’s a hidden detail, but without getting this right, the rest of the process runs on shaky ground.
Invest in a good magnetic stirrer for set-and-forget mixing. Prepare stock solutions in advance so there’s always some ready for urgent experiments. For extra stubborn powders, switch to higher-shear mixers, but watch out for foaming. Double-check the source and grade of F127—impurities or poor storage can slow down dissolving. Never rush with hot water; it just makes thicker clumps. Genuine progress in research comes from boring reliability, and careful prep with F127 pays off every time. Nobody celebrates dissolving solutions, but everyone notices when it goes wrong.
Poloxamers often confuse folks even in pharma and personal care because the codes sound so similar. But there’s a practical reason why chemists and product formulators ask you which one you mean. P407 and F127 both belong to a family of block copolymers, but they aren’t clones. The root of their difference lies in their structure. If you picture the polymer as a molecular chain, the P407 is bulkier, has a heavier hydrophobic middle, and packs a bigger punch in changing the structure of whatever it’s put in.
F127 isn’t as dense. Its main job comes down to making things smooth, spreading easily, or transforming into a thick gel at body temperature. This explains why F127 turns up in eye drops, skin creams, and hydrogels for wound dressings. It dissolves fast and creates a clear, soft base that feels light on the skin.
I’ve seen researchers sort through dozens of ingredients to solve one puzzle: How thick or how fluid does my final mix need to be? Trying to hit the right texture gets complicated if your polymer acts differently under changing temperatures. P407 gels at lower temperatures and remains solid at room temp, so medical professionals turn to it when they want a product that spreads when cold and holds fast at body warmth. Chemotherapy drugs and long-release injectables often need that trait, especially when you want to reduce injections or keep medicine working longer in the body.
F127 offers more flexibility at lower concentrations. That means fewer raw ingredients, lower cost, or less irritation on sensitive skin—key perks for products like baby ointments or eye gels. F127’s gentler touch translates to better patient tolerance, which makes a real difference in everyday treatment. I’ve seen children recoil from strong pharmaceutical gels and then relax after a switch to F127-based blends.
Both P407 and F127 have FDA approval in a range of uses, but bulk doesn’t always mean better. Too much P407 can lead to changes in cell membranes, so you always look for the lowest dose that can do the job. F127, though not perfect, gives you a bit more leeway; it’s less likely to irritate or linger in the body, which helps in chronic treatments.
Some folks forget that storage matters. P407-based mixtures can become rock-hard in a chilly pharmacy fridge—frustrating to anyone pressing a dispenser on a winter morning. F127 stands up better to lower temps without turning product into stone. The choice between them comes down to whether you want toughness or easy handling.
Every year, pharmacists and skincare researchers try new blends that combine both P407 and F127. The fusion aims to draw on the gel strength of P407 and the silky glide of F127. More work with nanoparticles and advanced drug delivery relies on getting this chemistry right. Solid research underpins these advances, so labs stick to small-scale tests before moving to production.
For folks formulating at home or in small labs, it pays to consult charts and look for manufacturer advice. I’ve found that talking with a chemist saves weeks of trial and error. And people living with allergies or chemical sensitivities need manufacturers to clearly label which poloxamer sits in the tube or vial. Openness about these differences builds trust, especially for those who rely on these compounds to manage serious illness every day.
| Names | |
| Preferred IUPAC name | α-Hydro-ω-hydroxypoly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) |
| Other names |
Pluronic F127 Synperonic PE/F127 Lutrol F127 Poloxamer 407 |
| Pronunciation | /pəˈlɒk.sə.mər pi ˌfɔːr ˈwʌn ˈsɛvən/ |
| Identifiers | |
| CAS Number | 9003-11-6 |
| Beilstein Reference | 1304646 |
| ChEBI | CHEBI:60710 |
| ChEMBL | CHEMBL1201528 |
| ChemSpider | 19822019 |
| DrugBank | DB06774 |
| ECHA InfoCard | ECHA InfoCard: 07-2119480726-30-0000 |
| EC Number | 9003-11-6 |
| Gmelin Reference | 14653 |
| KEGG | C18647 |
| MeSH | D020234 |
| PubChem CID | 24853 |
| RTECS number | TR6300000 |
| UNII | 68Y4CF58BV |
| UN number | Not regulated |
| Properties | |
| Chemical formula | (C3H6O)n(C2H4O)m |
| Molar mass | 12600 g/mol |
| Appearance | White solid powder |
| Odor | Odorless |
| Density | 1.015 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -2.1 |
| Vapor pressure | Negligible |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.450–1.460 |
| Viscosity | Viscosity: 3500 cP (20°C, 25% aqueous solution) |
| Dipole moment | 1.2 ± 0.2 D |
| Pharmacology | |
| ATC code | V06DA |
| Hazards | |
| Main hazards | May cause eye irritation. |
| GHS labelling | GHS labelling: "Not classified as hazardous according to GHS. |
| Pictograms | GHS07 |
| Signal word | No signal word |
| Hazard statements | No hazard statement. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| Flash point | > 122.7 °C (252.86 °F) |
| Autoignition temperature | > 370°C |
| LD50 (median dose) | LD50 (rat, oral): >40 g/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL: Not Established |
| REL (Recommended) | 10–30% |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Poloxamer 188 Poloxamer 105 Poloxamer 124 Poloxamer 235 Poloxamer 338 Poloxamer 331 |
